Dewan P A
Urology Unit, Adelaide Children's Hospital, South Australia.
Br J Urol. 1992 Jan;69(1):29-33. doi: 10.1111/j.1464-410x.1992.tb15453.x.
Injectable polytetrafluoroethylene (Polytef) has been used in many patients for vocal cord augmentation and for the management of urinary incontinence since the early 1960s and non-injectable forms have been used for sutures, hernia repair, replacement of the stapes, hip prostheses, cardiac valves and vascular grafts. Since 1984, many children have been treated with subureteric Polytef injection for the management of vesicoureteric reflex. Its use in young patients has heightened the concern about particle migration and carcinogenesis, particularly in view of the fact that the substance may be in the patient for decades. The available evidence does not confirm a significant carcinogenic effect in humans; rather it suggests that, if there is a risk, it is extremely low. However, human specimens, taken decades after the implantation of Polytef, and long-term, non-rodent animal experiments are needed to substantiate the probable safety of Polytef in children.
自20世纪60年代初以来，可注射聚四氟乙烯（特氟隆）已被用于许多患者的声带增厚及尿失禁治疗，不可注射形式的聚四氟乙烯则已用于缝合线、疝修补、镫骨置换、髋关节假体、心脏瓣膜及血管移植物。自1984年以来，许多儿童接受了输尿管下聚四氟乙烯注射治疗膀胱输尿管反流。其在年轻患者中的使用加剧了人们对颗粒迁移和致癌作用的担忧，尤其是考虑到该物质可能在患者体内留存数十年。现有证据并未证实其对人类有显著致癌作用；相反，这表明即便存在风险，也是极低的。然而，需要获取植入聚四氟乙烯数十年后的人体标本以及长期非啮齿动物实验，以证实聚四氟乙烯在儿童中可能的安全性。
